Special Issue "Transdermal Nano-Based Drug Delivery Systems for Wound Healing"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 31 October 2023 | Viewed by 1520

Special Issue Editor

Tissue Biology Research Unit, Department of Surgery, University Children’s Hospital Zurich, 8032 Zurich, Switzerland
Interests: human skin; keratinocytes; endothelial cells; skin substitutes; stem cells; melanocytes; adipose-dervied stem cells; fat tissue; skin inflammation; immune cells; skin adipocyte progenitors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Despite the significant progress that has been made in clinical medicine, non-healing wounds such as diabetic foot, venous leg ulcers, pressure ulcers, and other types of injuries propose a serious world health problem. The current limitation for therapies involving proteins, genes, and small molecule drugs has been a delivery system that can effectively enable their full therapeutic benefits. Therefore, innovative drug-delivery systems that are based on nanotechnology for wound treatment have been developed. They can maintain high drug bioactivity bioavailability and can facilitate its release or presentation within the wound at a physiologically relevant rate and duration. In this Special Issue of Pharmaceutics, we aim to highlight recent advances in nanotechnolodgy-based delivery systems for wound healing applications. In particular, we will focus on those systems using hydrogels, scaffolds, biologics, complexes, and coacervates to discuss their advantages and potential drawbacks.

Dr. Agnes Klar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • biomateriasl
  • coacervate
  • controlled release
  • biologics
  • drug delivery
  • hydrogel
  • microparticles
  • scaffold
  • wound healing

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Amitriptyline-Based Biodegradable PEG-PLGA Self-Assembled Nanoparticles Accelerate Cutaneous Wound Healing in Diabetic Rats
Pharmaceutics 2022, 14(9), 1792; https://doi.org/10.3390/pharmaceutics14091792 - 26 Aug 2022
Cited by 2 | Viewed by 1169
The aim of this work was to study the healing activity of amitriptyline (Amitrip) in rat diabetic wounds. A nanoformula of the drug was prepared as Amitrip-based biodegradable PEG-PLGA self-assembled nanoparticles (Amitrip-NPs) with a mean particle size of 67.4 nm. An in vivo [...] Read more.
The aim of this work was to study the healing activity of amitriptyline (Amitrip) in rat diabetic wounds. A nanoformula of the drug was prepared as Amitrip-based biodegradable PEG-PLGA self-assembled nanoparticles (Amitrip-NPs) with a mean particle size of 67.4 nm. An in vivo investigation was conducted to evaluate the wound-healing process of Amitrip-NPs in streptozotocin-induced diabetic rats. Wound contraction was accelerated in rats treated with Amitrip-NPs. Histological examinations confirmed these findings, with expedited remodeling and collagen deposition in the NPs-treated animals. The formula showed anti-inflammatory activities as demonstrated by inhibition of interleukin-6 (IL-6) expression and tumor necrosis factor-α (TNF-α) expression, as well as enhanced expression of interleukin-10 (IL-10). In addition, Amitrip-NPs protected against malondialdehyde (MDA) buildup and superoxide dismutase (SOD) and glutathione peroxidase (GPx) enzymatic exhaustion. The pro-collagen activity of Amitrip-NPs was confirmed by the observed enhancement of hydroxyproline wounded skin content, upregulation of Col 1A1 mRNA expression and immune expression of collagen type IV expression. Further, Amitrip-NPs significantly increased expression transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor-A (VEGF-A), platelet-derived growth factor-B (PDGF-B) and cluster of differentiation 31 (CD31). In conclusion, the developed Amitrip-NPs expedited wound healing in diabetic rats. This involves anti-inflammatory, antioxidant, pro-collagen and angiogenic activities of the prepared NPs. This opens the gate for evaluating the usefulness of other structurally related tricyclic antidepressants in diabetic wounds. Full article
(This article belongs to the Special Issue Transdermal Nano-Based Drug Delivery Systems for Wound Healing)
Show Figures

Graphical abstract

Back to TopTop